STOCK TITAN

Abbott Laboratories - ABT STOCK NEWS

Welcome to our dedicated news page for Abbott Laboratories (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Abbott Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Abbott Laboratories's position in the market.

Rhea-AI Summary
Abbott reported first-quarter 2024 results with sales of $10.0 billion, driven by strong underlying base business performance. Organic sales growth for the underlying base business was 10.8%, marking the fifth consecutive quarter of double-digit growth. The company announced first-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98. Abbott narrowed its full-year 2024 EPS guidance range, projecting full-year diluted EPS on a GAAP basis of $3.25 to $3.40 and adjusted diluted EPS of $4.55 to $4.70. The company also launched new products and received FDA approvals for innovative treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Abbott's TriClip receives FDA approval for treating tricuspid regurgitation, offering a safe and minimally invasive option. The approval follows positive trial results showing significant symptom improvement and quality of life benefits. TriClip is designed to repair leaky tricuspid valves, providing an alternative to high-risk open-heart surgery for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
-
Rhea-AI Summary
Abbott's i-STAT TBI cartridge receives FDA clearance for whole blood use, enabling rapid assessment of mild traumatic brain injury at patient's bedside. Test provides lab-quality results in 15 minutes, expanding testing capabilities beyond traditional healthcare settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
Rhea-AI Summary
Abbott (ABT) to release first-quarter 2024 financial results on April 17, with a live webcast of the earnings conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
-
Rhea-AI Summary
Abbott highlights four key factors for individuals with diabetes to safeguard heart health, emphasizing the importance of prioritizing health over neglecting it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.83%
Tags
none
-
Rhea-AI Summary
Abbott extends partnership with Real Madrid to combat childhood malnutrition and promote healthy habits. The collaboration includes nutrition education, malnutrition screening, and nutritional guidance for athletes, aiming to improve the lives of children globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
partnership
Rhea-AI Summary
Abbott announces new data showing improved HbA1c results in Type 2 diabetes patients using GLP-1 medicines with FreeStyle Libre technology. The studies presented at a conference highlight significant benefits of combining these treatments for better glucose management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
-
Rhea-AI Summary
Abbott (ABT) declares a quarterly common dividend of 55 cents per share, marking the 401st consecutive dividend since 1924. The cash dividend will be paid on May 15, 2024, to shareholders of record on April 15, 2024. Abbott has raised its dividend for 52 years and is part of the S&P 500 Dividend Aristocrats Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
dividends
-
Rhea-AI Summary
Abbott's TriClip system for tricuspid regurgitation receives positive review from FDA advisory committee, showing safety, effectiveness, and quality-of-life benefits. The device has been approved in over 50 countries and has treated over 10,000 patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
none
Rhea-AI Summary
Abbott (NYSE:ABT) and Blood Centers of America (BCA) have partnered to launch a mixed reality experience for blood donors, designed to ease feelings of anxiety and increase donor retention. Results from the pilot study show that 68.4% of donors who reported pre-donation anxiety felt less anxious using mixed reality, and 89.2% of donors said they were likely to donate blood again. The technology aims to attract new donors and motivate a younger generation to give blood, addressing the global challenge of sustaining a reliable blood supply.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
Abbott Laboratories

NYSE:ABT

ABT Rankings

ABT Stock Data

189.50B
1.72B
0.54%
77.02%
0.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
North Chicago

About ABT

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.